Psoriatic erythroderma: comparative patient profile and association with psoriatic arthritis
- Authors: Bogdanova E.V.1
-
Affiliations:
- State Research Center of Dermatovenereology and Cosmetology
- Issue: Vol 98, No 6 (2022)
- Pages: 73-80
- Section: ORIGINAL STUDIES
- URL: https://journals.rcsi.science/0042-4609/article/view/117638
- DOI: https://doi.org/10.25208/vdv1328
- ID: 117638
Cite item
Full Text
Abstract
Background. Psoriatic erythroderma is rare and one of the most severe forms of psoriasis characterized by involvement of 80–90% of body surface area.
Aims. To compare clinical and demographic characteristics of patients with psoriasis, depending on presence of psoriatic erythroderma in medical history; to assess the association between psoriatic arthritis and a history of psoriatic erythroderma.
Materials and methods. Patients aged 18 years and older with a duration of psoriasis of >10 years, from the psoriasis patients registry were included.
Comparison of continuous quantitative variables was performed using t-test or Mann–Whitney U-test. The χ2 test or Fisher's exact test was used to compare qualitative binary variables.
The odds ratio of psoriatic arthritis in patients with and without a history of psoriatic erythroderma was calculated, unadjusted and adjusted for other independent variables.
Results. The number of patients included in the analysis was 1,870. A history of psoriatic erythroderma (PE) had 227 (12.1%) of them. There were no significant differences in patient age at inclusion to the registry (47.1 ± 13.1 years vs. 47.7 ± 13.3 years), and prevalence of PE among men and women (12.6% vs. 11. 4%).
Higher prevalence of arterial hypertension (47.9% vs 32.7%), angina pectoris (6.4% vs. 1.9%), myocardial infarction (3.2% vs. 1.0%), biliary dyskynesia (14.3% vs. 3.9%), fatty liver (12.2% vs. 7.7%), cholelithiasis (8.6% vs. 3.6%), and toxic liver disease (2.2% vs. 0.5%) among patients with vs without history of PE was found.
Psoriatic arthritis was diagnosed in 67.0% patients with a history of psoriatic erythroderma. The odds of having psoriatic arthritis in patients with a history of psoriatic erythroderma were 4 times higher than in patients without erythroderma: 4.043 [2.975–5.493]. When adjusted for sex, age, duration of psoriasis, and body mass index, the odds ratio and statistical significance were maintained: 4.064 [2.939–5.619].
Conclusions. Compared to patients without PE those with a history of psoriatic erythroderma have a greater comorbidity burden: a higher prevalence of cardiovascular diseases, diseases of the liver and biliary tract. A significant association between psoriatic arthritis and a history of PE was established.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Elena V. Bogdanova
State Research Center of Dermatovenereology and Cosmetology
Author for correspondence.
Email: bogdanova@cnikvi.ru
ORCID iD: 0000-0002-0662-2682
SPIN-code: 6372-2237
Scopus Author ID: 57205267691
MD, Cand. Sci. (Med.)
Russian Federation, Korolenko str., 3, bldg 6, 107076, MoscowReferences
- Псориаз. Клинические рекомендации Российского общества дерматовенерологов и косметологов. 2020. http://www.cr.minzdrav.gov.ru/schema/234_1. [Psoriasis arthropathic. Psoriatic arthritis. Clinical guidelines of Russian society of dermatovenereologists and cosmetologists and Association of rheumatologists of Russia. 2021. http://www.cr.minzdrav.gov.ru/schema/234_1]
- Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, et al. National Psoriasis Foundation Medical Board. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655–662. doi: 10.1016/j.jaad.2009.05.048
- Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989;21:985–991
- Foss MG, Nyckowski T, Steffes W. Erythrodermic Psoriasis Exacerbated by Bupropion. Cureus. 2021;13(10):e18460. doi: 10.7759/cureus.18460
- Potter KA, Motaparthi K, Schoch JJ. Erythrodermic psoriasis after discontinuation of ixekizumab. JAAD Case Rep. 2017;4(1):22–23. doi: 10.1016/j.jdcr.2017.06.026
- Matos-Pires E, Campos S, Mendes-Bastos P, João A, Fernandes C. Erythrodermic psoriasis induced by bupropion. J Eur Acad Dermatol Venereol. 2017;31(2):e129-e130. doi: 10.1111/jdv.13876
- Tichy M. Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab. Postepy Dermatol Alergol. 2019;36(4):495–497. doi: 10.5114/ada.2019.87454
- Кубанов А.А., Богданова Е.В. Эпидемиология псориаза в Российской Федерации (по данным регистра). Вестник дерматологии и венерологии. 2022;98(1):33–41. [Kubanov AA, Bogdanova EV. Epidemiology of psoriasis in the Russian Federation according to the patient registry. Vestnik dermatologii i venerologii. 2022;98(1):33–41 (In Russ.)] doi: 10.25208/vdv1268
- Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433–442. doi: 10.1097/HJH.0b013e32835bcce1
- Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27 Suppl 3:12-29. doi: 10.1111/jdv.12163
- Ahlehoff O, Gislason GH, Charlot M, Jørgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147–157. doi: 10.1111/j.1365-2796.2010.02310.x
- Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062. doi: 10.1161/JAHA.113.000062
- Yamazaki F, Takehana K, Tanaka A, Son Y, Ozaki Y, Tanizaki H. Relationship between Psoriasis and Prevalence of Cardiovascular Disease in 88 Japanese Patients. J Clin Med. 2021;10(16):3640. doi: 10.3390/jcm10163640
- Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54. doi: 10.1038/nutd.2012.26
- Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91. doi: 10.1001/2013.jamadermatol.406
- Coto-Segura P, Eiris-Salvado N, González-Lara L, Queiro-Silva R, Martinez-Camblor P, Maldonado-Seral C, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol. 2013;169(4):783–793. doi: 10.1111/bjd.12473
- Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–662. doi: 10.1016/j.jaad.2012.08.015
- Singh S, Young P, Armstrong AW. Relationship between psoriasis and metabolic syndrome: a systematic review. G Ital Dermatol Venereol. 2016;151(6):663–677.
- Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS One. 2017;12(7):e0181039. doi: 10.1371/journal.pone.0181039
- Zabotti A, De Lucia O, Sakellariou G, Batticciotto A, Cincinelli G, Giovannini I, et al. Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. Rheumatol Ther. 2021;8(4):1519–1534. doi: 10.1007/s40744-021-00378-w
- Liu P, Kuang Y, Ye L, Peng C, Chen W, Shen M, et al. Predicting the Risk of Psoriatic Arthritis in Plaque Psoriasis Patients: Development and Assessment of a New Predictive Nomogram. Front Immunol. 2022;12:740968. doi: 10.3389/fimmu.2021.740968
- Ogdie A, Eder L. The need for strategies to address obesity and psoriatic arthritis prevention in psoriasis. Br J Dermatol. 2020;182(3):523–524. doi: 10.1111/bjd.18595
- Chen Z, Wang Y, Lan X, Yang M, Ding L, Li G, et al. Nomogram for accurate and quantitative prediction of the risk of psoriatic arthritis in Chinese adult patients with moderate and severe plaque psoriasis. Eur J Dermatol. 2021. doi: 10.1684/ejd.2021.4095
- Green A, Shaddick G, Charlton R, Snowball J, Nightingale A, Smith C, et al. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br J Dermatol. 2020;182(3):714–720. doi: 10.1111/bjd.18227
- Xie W, Huang H, Deng X, Gao D, Zhang Z. Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2021;84(3):701–711. doi: 10.1016/j.jaad.2020.08.060
- Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R, et al. The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis Rheumatol. 2016;68(4):915–923. doi: 10.1002/art.39494
- Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153–166. doi: 10.1038/s41584-019-0175-0
- Кубанов А.А., Богданова Е.В. Что такое регистры пациентов и зачем они нужны (на примере регистров пациентов с псориазом). Вестник РАМН. 2021;76(2):177–186. doi: https://doi.org/10/15690/vramn1454 [Kubanov AA, Bogdanova EV. What Are Patient Registries And Why Are They Needed (Through a Number of Examples of Psoriasis Registries). Annals of the Russian Academy of Medical Sciences. 2021;76(2):177–186 (In Russ.)] doi: https://doi.org/10/15690/vramn1454
Supplementary files
